DIVISLAB Divi's Laboratories Q2 FY25 results (Jul–Sep 2024) and concall
Divi's delivered strong Q2 with 23% revenue growth and 47% PAT growth driven by custom synthesis momentum crossing 51% of revenue. The company established SPPS infrastructure with multiple 500-litre reactors for GLP-1 fragments, working with multiple innovators across commercialized, Phase II and Phase III molecules. Kakinada Phase-wise production expected from December 2024. Generic business saw double-digit volume growth but pricing pressure persists across the board.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 2,302 |
| EBITDA | 729 |
| Net profit | 518 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
